Patents by Inventor Michael D. Howell

Michael D. Howell has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 12280054
    Abstract: The present application provides methods of treating hidradenitis suppurativa in a patient in need thereof, comprising administering to the patient a therapeutically effective amount of a compound which inhibits JAK1 and/or JAK2, or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: April 13, 2022
    Date of Patent: April 22, 2025
    Assignee: Incyte Corporation
    Inventors: Michael D. Howell, Paul Smith
  • Patent number: 12203942
    Abstract: Biomarkers are provided that are predictive of a subject's responsiveness to a JAK inhibitor. The biomarkers, compositions, and methods described herein are useful in selecting appropriate treatment modalities for a subject having, suspected of having, or at risk of developing Graft-Versus-Host Disease.
    Type: Grant
    Filed: October 8, 2020
    Date of Patent: January 21, 2025
    Assignee: Incyte Corporation
    Inventors: Michael D. Howell, Sherry Owens, Michael A. Pratta
  • Publication number: 20240358680
    Abstract: This disclosure relates to JAK1 pathway inhibitors and their use in treating vitiligo.
    Type: Application
    Filed: March 7, 2024
    Publication date: October 31, 2024
    Inventors: Paul Smith, Kurt Andrew Brown, Michael D. Howell, Fiona Kuo, James Lee, Leandro Luiz Dos Santos, Beth Rumberger
  • Patent number: 12099068
    Abstract: Biomarkers are provided that are predictive of a subject's responsiveness to a therapy comprising a JAK inhibitor. The biomarkers, compositions, and methods described herein are useful in selecting appropriate treatment modalities for a subject having, suspected of having, or at risk of developing Graft-Versus-Host Disease.
    Type: Grant
    Filed: May 20, 2022
    Date of Patent: September 24, 2024
    Assignee: Incyte Corporation
    Inventors: Michael D. Howell, Hao Liu, Michael A. Pratta
  • Patent number: 11957661
    Abstract: This disclosure relates to JAK1 pathway inhibitors and their use in treating vitiligo.
    Type: Grant
    Filed: December 8, 2021
    Date of Patent: April 16, 2024
    Assignee: Incyte Corporation
    Inventors: Paul Smith, Kurt Andrew Brown, Michael D. Howell, Fiona Kuo, James Lee, Leandro Luiz Dos Santos, Beth Rumberger
  • Publication number: 20230220478
    Abstract: Biomarkers are provided that are associated with or predictive of a subject's responsiveness to a JAK inhibitor. The biomarkers, compositions, and methods described herein are useful in selecting appropriate treatment modalities for a subject having, suspected of having, or at risk of developing vitiligo.
    Type: Application
    Filed: December 28, 2022
    Publication date: July 13, 2023
    Inventors: Michael D. Howell, Sherry Owens, Beth Rumberger, Huiqing Liu
  • Patent number: 11624751
    Abstract: Biomarkers are provided that are associated with or predictive of a subject's responsiveness to a JAK inhibitor. The biomarkers, compositions, and methods described herein are useful in selecting appropriate treatment modalities for a subject having, suspected of having, or at risk of developing vitiligo.
    Type: Grant
    Filed: March 18, 2020
    Date of Patent: April 11, 2023
    Assignee: Incyte Corporation
    Inventors: Michael D. Howell, Sherry Owens, Beth Rumberger, Huiqing Liu
  • Patent number: 11584961
    Abstract: Biomarkers are provided that are predictive of a subject's responsiveness to a therapy comprising a JAK inhibitor. The biomarkers, compositions, and methods described herein are useful in selecting appropriate treatment modalities for a subject having, suspected of having, or at risk of developing an inflammatory skin disease.
    Type: Grant
    Filed: March 29, 2019
    Date of Patent: February 21, 2023
    Assignee: Incyte Corporation
    Inventors: Michael D. Howell, Huiqing Liu
  • Publication number: 20230027606
    Abstract: Biomarkers are provided that are predictive of a subject's responsiveness to a therapy comprising a JAK inhibitor. The biomarkers, compositions, and methods described herein are useful in selecting appropriate treatment modalities for a subject having, suspected of having, or at risk of developing Graft-Versus-Host Disease.
    Type: Application
    Filed: May 20, 2022
    Publication date: January 26, 2023
    Inventors: Michael D. Howell, Hao Liu, Michael A. Pratta
  • Publication number: 20220241286
    Abstract: The present application provides methods of treating hidradenitis suppurativa in a patient in need thereof, comprising administering to the patient a therapeutically effective amount of a compound which inhibits JAK1 and/or JAK2, or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: April 13, 2022
    Publication date: August 4, 2022
    Inventors: Michael D. Howell, Paul Smith
  • Patent number: 11372003
    Abstract: Biomarkers are provided that are predictive of a subject's responsiveness to a therapy comprising a JAK inhibitor. The biomarkers, compositions, and methods described herein are useful in selecting appropriate treatment modalities for a subject having, suspected of having, or at risk of developing Graft-Versus-Host Disease.
    Type: Grant
    Filed: April 11, 2019
    Date of Patent: June 28, 2022
    Assignee: Incyte Corporation
    Inventors: Michael D. Howell, Hao Liu, Michael A. Pratta
  • Publication number: 20220175731
    Abstract: This disclosure relates to JAK1 pathway inhibitors and their use in treating vitiligo.
    Type: Application
    Filed: December 8, 2021
    Publication date: June 9, 2022
    Inventors: Paul Smith, Kurt Andrew Brown, Michael D. Howell, Fiona Kuo, James Lee, Leandro Luiz Dos Santos, Beth Rumberger
  • Patent number: 11304949
    Abstract: The present application provides methods of treating hidradenitis suppurativa in a patient in need thereof, comprising administering to the patient a therapeutically effective amount of a compound which inhibits JAK1 and/or JAK2, or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: March 29, 2019
    Date of Patent: April 19, 2022
    Assignee: Incyte Corporation
    Inventors: Michael D. Howell, Paul Smith
  • Publication number: 20210123931
    Abstract: Biomarkers are provided that are predictive of a subject's responsiveness to a JAK inhibitor. The biomarkers, compositions, and methods described herein are useful in selecting appropriate treatment modalities for a subject having, suspected of having, or at risk of developing Graft-Versus-Host Disease.
    Type: Application
    Filed: October 8, 2020
    Publication date: April 29, 2021
    Inventors: Michael D. Howell, Sherry Owens, Michael A. Pratta
  • Publication number: 20210123930
    Abstract: Biomarkers are provided that are predictive of a subject's responsiveness to a JAK inhibitor. The biomarkers, compositions, and methods described herein are useful in selecting appropriate treatment modalities for a subject having, suspected of having, or at risk of developing Graft-Versus-Host Disease.
    Type: Application
    Filed: October 8, 2020
    Publication date: April 29, 2021
    Inventors: Michael D. Howell, Sherry Owens, Michael A. Pratta
  • Publication number: 20200348313
    Abstract: Biomarkers are provided that are associated with or predictive of a subject's responsiveness to a JAK inhibitor. The biomarkers, compositions, and methods described herein are useful in selecting appropriate treatment modalities for a subject having, suspected of having, or at risk of developing vitiligo.
    Type: Application
    Filed: March 18, 2020
    Publication date: November 5, 2020
    Inventors: Michael D. Howell, Sherry Owens, Beth Rumberger, Huiqing Liu
  • Publication number: 20200063188
    Abstract: Biomarkers are provided that are predictive of a subject's responsiveness to a therapy comprising a JAK inhibitor. The biomarkers, compositions, and methods described herein are useful in selecting appropriate treatment modalities for a subject having, suspected of having, or at risk of developing an inflammatory skin disease.
    Type: Application
    Filed: March 29, 2019
    Publication date: February 27, 2020
    Inventors: Michael D. Howell, Huiqing Liu
  • Publication number: 20190328739
    Abstract: The present application provides methods of treating hidradenitis suppurativa in a patient in need thereof, comprising administering to the patient a therapeutically effective amount of a compound which inhibits JAK1 and/or JAK2, or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: March 29, 2019
    Publication date: October 31, 2019
    Inventors: Michael D. Howell, Paul Smith
  • Publication number: 20190331697
    Abstract: Biomarkers are provided that are predictive of a subject's responsiveness to a therapy comprising a JAK inhibitor. The biomarkers, compositions, and methods described herein are useful in selecting appropriate treatment modalities for a subject having, suspected of having, or at risk of developing Graft-Versus-Host Disease.
    Type: Application
    Filed: April 11, 2019
    Publication date: October 31, 2019
    Inventors: Michael D. Howell, Hao Liu, Michael A. Pratta
  • Patent number: 6837169
    Abstract: An aluminum vehicle carrier railcar has an end door system attached to at least one end of an upper structure thereof including an end door pair, each pivoting about a vertical axis and having an inner and outer door member. The members move from an aligned side-by-side closed position to an open overlapping, nested position exterior and adjacent a railcar side. The members have the same exterior side facing away from the railcar in both the open and the closed positions. A linkage assembly extends from each pivot axis to the members, and each includes a pivotable main arm, an inner arm extending from the main arm to the inner member and an outer arm extending from the main arm to the outer member. Guides extend between the members and between the outer door member and the railcar to guide the relative motion of the members.
    Type: Grant
    Filed: April 17, 2003
    Date of Patent: January 4, 2005
    Assignee: JAC Patent Company
    Inventors: Daryl H. Michaelian, Joel C. Haas, Michael D. Howell, Jose M. Cintron, Alan B. C. Dixon, Joe F. Englehart, Bill W. Pankey, Ronnie A. Shand, William J. Spicer, Martin E. Pettet